title: Oral use of iron with vitamin C in hemodialyzed patients.
abstract: OBJECTIVE
  To investigate if oral use of Sorbifer Durules (EGIS Pharmaceutical Ltd, Budapest, Hungary) (1 tablet/d) is adequate for the maintenance of serum iron and vitamin C in normal range during recombinant human erythropoietin treatment in hemodialyzed patients. One tablet of Sorbifer Durules contains 100 mg of Fe(2+) and 60 mg of vitamin C.
  
  
  METHODS
  Short-term, open-label clinical trial.
  
  
  METHODS
  Hemodialysis units.
  
  
  METHODS
  Twenty-four adult patients with end-stage renal disease on hemodialysis.
  
  
  METHODS
  Four-week treatment period of Sorbifer Durules, preceded and followed by iron and vitamin C washout periods.
  
  
  METHODS
  Fasting predialysis serum samples were collected on days 0, 28, 56, and 84 to determine hematocrit, blood hemoglobin, serum iron, total iron-binding capacity, transferrin saturation, ferritin, vitamin C, and plasma oxalate.
  
  
  RESULTS
  Four-week treatment in hemodialyzed patients by Sorbifer Durules led to significant increase of hematocrit, blood hemoglobin, serum iron and vitamin C. This treatment did not influence the level of plasma oxalate.
  
  
  CONCLUSIONS
  Oral dose of one tablet of Sorbifer Durules per day is adequate for the maintenance of serum iron in normal range during recombinant human erythropoietin treatment in hemodialyzed patients. This treatment simultaneously prevented the development of serum vitamin C deficiency and did not lead to further increase of plasma oxalate in these patients.
authors.affiliation: Internal Medicine and Nephrology, Nephrological Clinic, University Hospital of L.Pasteur, Kosice, Slovak Republic.
authors.forename: Miroslav
authors.initials: M
authors.lastname: Mydlík
authors.forename: Katarína
authors.initials: K
authors.lastname: Derzsiová
authors.forename: Ján
authors.initials: J
authors.lastname: Boldizsár
authors.forename: Mária
authors.initials: M
authors.lastname: Hríbiková
authors.forename: Jozefína
authors.initials: J
authors.lastname: Petrovicová
mesh_terms: D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000517:prevention & control*; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000097:blood; D003404:Creatinine / Q000097:blood; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000097:blood / Q000378:metabolism*; D000090463:Iron Deficiencies; D019266:Iron, Dietary / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010070:Oxalates / Q000097:blood; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects; D014168:Transferrin / Q000378:metabolism
chemical_list: D006454:Hemoglobins; D019266:Iron, Dietary; D010070:Oxalates; D011994:Recombinant Proteins; D014168:Transferrin; D004921:Erythropoietin; D005293:Ferritins; D003404:Creatinine; D007501:Iron; D001205:Ascorbic Acid